Alpha Tau Medical Rises on Tolmar Deal to Commercialize Prostate Cancer Therapy

Shares of Alpha Tau Medical rose Wednesday after it said it will collaborate with Tolmar International to bring localized alpha radiation cancer therapy to prostate cancer patients in the United ...

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the ...
Globes

Alpha Tau teams with Tolmar on lucrative prostate cancer deal

Alpha Tau CEO Uzi Sofer: "Tolmar is a well-established company in the field of urology in the US. We decided to grant exclusivity for one of our most promising but least advanced indications. In the ...
UroToday

ASCO 2026: Discussant - Moving Beyond Beta-Emitters: The Next Generation Radioligand Therapies in Prostate Cancer

The 2026 ASCO annual meeting featured a plenary session and a discussant presentation by Dr. Jeremie Calais discussing two ...
Nasdaq

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the ...
Marketplace

The next cancer drug boom may depend on radioactive waste

Targeted alpha therapies could better attack tumors while reducing damage to healthy tissue.